Sign in
CompletedPhase 3

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

Key facts

Who runs it
Vivacelle Bio
Where
Chandler, Kansas City, Portland, Savannah, and Winston-Salem, United StatesSee the 5 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
39 people enrolled
Started
6 Aug 2024
Ended
29 Jun 2026
Type of study
Interventional
Treatments tested
  • VBI-S
Record updated
26 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Male or female at least 18 years of age
  • Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml
  • Patient has a mean blood pressure < 65 mmHg that is unresponsive to fluids currently available on the market
  • Sequential Organ Failure Assessment (SOFA) score ≥ 5
  • Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:; Lactate > 2 mmol/L; Fever > 38.3°C, or 101°F; Hypothermia < 36°C core temperature (<96.8°F); Heart rate > 90; Tachypnea (respiratory rate ≥ 20/min); White blood cell count >12,000 or less than 4,000, or with >10% "bands" (immature forms); Elevated procalcitonin in serum (≥ 2ng/ml); Arterial hypoxemia (PaO2/FiO2 < 300); Creatinine increase > 0.5 mg/dL since hospital admission; INR > 1.5 or aPTT > 60 seconds
  • Documented dysregulated host response to an infection as indicated by an increase in SOFA score by ≥ 2 points after an infection per the SEPSIS 3 guideline
  • Receiving vasopressors to maintain the target MAP of 65 mmHg

Who cannot take part

  • Emergency major surgery
  • Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs are for COVID-19
  • Acute coronary syndrome
  • Diagnosis of acute Hepatitis B or C
  • Patients with a known allergy to soybeans or eggs
  • Hematologic or coagulation disorders including thrombocytopenia (platelet count <50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure
  • White blood cell count of < 1000 mm3
  • Patients with a ventricular assist device
  • Pregnant
  • Acute bronchospasm
  • Acute Mesenteric ischemia
  • Patient is hypervolemic with assessment by physician or physician extender ultrasound 12 hours before infusion of VBI-S if hypervolemia is suspected
  • Patient expected to expire within 12 hours
  • Patients with disturbances in normal fat metabolism such as pathologic hyperlipemia, lipid nephrosis, or acute pancreatitis with hyperlipidemia

Where in United States

  • Dignity Health - Chandler Regional Medical CenterChandler, United States
  • University HealthKansas City, United States
  • Oregon Health & Science University (OHSU)Portland, United States
  • Memorial Health University Medical CenterSavannah, United States
  • Novant HealthcareWinston-Salem, United States

About the trial

What the trial wants to find out

This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

The group in the trial

  • VBI-STreatment being tested

    Treatment with VBI-S

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock
Record updated
26 October 2026